Newsfile Corp
31 Jul 2026, 13:00 UTC · 14w ago
Impact · against what's priced in
CAPR faces severe downside as an investigation into securities law violations follows a critical FDA failure and allegations of data manipulation. DKS, PLNT, and PZZA are minimally affected as they are merely listed as other targets of the same law firm's investigations in a general news feed.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
FDA staff concluded that deramiocel's data does not provide 'substantial evidence of effectiveness' and noted the application relied on only one pivotal trial.
More negative than 99% of claims this week
Capricor Therapeutics shares fell more than 60% following the release of FDA briefing documents.
Continue reading
5 related stories
The FDA's conclusion that deramiocel lacks substantial evidence of effectiveness, combined with allegations of statistical manipulation and a resulting 60% price collapse, creates a high probability of regulatory failure and legal liability.
Read from the article alone
No priced-in read yet
The company is listed as a subject of an investigation by Block & Leviton to recover investor losses, though specific details of the alleged violations are not provided in this text.
Read from the article alone
No priced-in read yet
The company is mentioned as being subject to a lawsuit by Block & Leviton regarding investor losses, without further detail on the underlying cause.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 98% of claims this week
The FDA raised concerns that Capricor made multiple changes to its statistical analysis plan after the study was completed to potentially generate a positive outcome.
More negative than 94% of claims this week
Law firm Block & Leviton is investigating Capricor Therapeutics for potential securities law violations regarding representations of the regulatory path for deramiocel.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is under investigation for securities law violations after the FDA questioned its clinical data, leading to a 60% share price drop.
More negative than 93% of ticker scores this week
The company is mentioned as the subject of an investigation by Block & Leviton to recover investor losses.
More negative than 93% of ticker scores this week
The company is mentioned in relation to a lawsuit by Block & Leviton regarding investor losses.
More negative than 93% of ticker scores this week
The company is mentioned as the subject of an investigation by Block & Leviton to recover investor losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
7h ago
−29.6%
Price agrees with the score
$140.82 vs $199.91 close before publication (Jul 30) · not market-adjusted
DKS chart →+7.7%
Price is moving against the score
$60.31 vs $55.98 close before publication (Jul 30) · not market-adjusted
PLNT chart →+114.8%
Price is moving against the score
$9.00 vs $4.19 close before publication (Jul 30) · not market-adjusted
CAPR chart →
